Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and antiretroviral-free remission. BnAbs can neutralize HIV-1 and target infected cells for elimination. Concerns about HIV-1 re...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.710044/full |
| _version_ | 1818883857740464128 |
|---|---|
| author | Denise C. Hsu Denise C. Hsu John W. Mellors Sandhya Vasan Sandhya Vasan |
| author_facet | Denise C. Hsu Denise C. Hsu John W. Mellors Sandhya Vasan Sandhya Vasan |
| author_sort | Denise C. Hsu |
| collection | DOAJ |
| description | Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and antiretroviral-free remission. BnAbs can neutralize HIV-1 and target infected cells for elimination. Concerns about HIV-1 resistance to single bnAbs have led to studies of bnAb combinations with non-overlapping resistance profiles. This review focuses on the potential for bnAbs to induce HIV-1 remission, either alone or in combination with latency reversing agents, therapeutic vaccines or other novel therapeutics. Key topics include preliminary activity of bnAbs in preclinical models and in human studies of HIV-1 remission, clinical trial designs, and antibody design strategies to optimize pharmacokinetics, coverage of rebound-competent virus, and enhancement of cellular immune functions. |
| first_indexed | 2024-12-19T15:40:19Z |
| format | Article |
| id | doaj.art-5422e86f933a43fe90861b3bd29161a7 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T15:40:19Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5422e86f933a43fe90861b3bd29161a72022-12-21T20:15:29ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-07-011210.3389/fimmu.2021.710044710044Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?Denise C. Hsu0Denise C. Hsu1John W. Mellors2Sandhya Vasan3Sandhya Vasan4U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United StatesHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United StatesDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United StatesU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United StatesHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United StatesMany broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and antiretroviral-free remission. BnAbs can neutralize HIV-1 and target infected cells for elimination. Concerns about HIV-1 resistance to single bnAbs have led to studies of bnAb combinations with non-overlapping resistance profiles. This review focuses on the potential for bnAbs to induce HIV-1 remission, either alone or in combination with latency reversing agents, therapeutic vaccines or other novel therapeutics. Key topics include preliminary activity of bnAbs in preclinical models and in human studies of HIV-1 remission, clinical trial designs, and antibody design strategies to optimize pharmacokinetics, coverage of rebound-competent virus, and enhancement of cellular immune functions.https://www.frontiersin.org/articles/10.3389/fimmu.2021.710044/fullbroadly neutralizing HIV-1 antibodyHIV remissionHIV cureHIV immunotherapyHIV therapeutics |
| spellingShingle | Denise C. Hsu Denise C. Hsu John W. Mellors Sandhya Vasan Sandhya Vasan Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission? Frontiers in Immunology broadly neutralizing HIV-1 antibody HIV remission HIV cure HIV immunotherapy HIV therapeutics |
| title | Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission? |
| title_full | Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission? |
| title_fullStr | Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission? |
| title_full_unstemmed | Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission? |
| title_short | Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission? |
| title_sort | can broadly neutralizing hiv 1 antibodies help achieve an art free remission |
| topic | broadly neutralizing HIV-1 antibody HIV remission HIV cure HIV immunotherapy HIV therapeutics |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.710044/full |
| work_keys_str_mv | AT denisechsu canbroadlyneutralizinghiv1antibodieshelpachieveanartfreeremission AT denisechsu canbroadlyneutralizinghiv1antibodieshelpachieveanartfreeremission AT johnwmellors canbroadlyneutralizinghiv1antibodieshelpachieveanartfreeremission AT sandhyavasan canbroadlyneutralizinghiv1antibodieshelpachieveanartfreeremission AT sandhyavasan canbroadlyneutralizinghiv1antibodieshelpachieveanartfreeremission |